Literature DB >> 8846114

Melatonin and its new agonist S-20098 restore synchronized sleep fragmented by experimental trypanosome infection in the rat.

G Grassi-Zucconi1, M Semprevivo, E Mocaer, K Kristensson, M Bentivoglio.   

Abstract

The experimental infection with the parasite Trypanosoma brucei in the rat provides a unique model of dysfunction of the sleep regulatory mechanisms, because the length of synchronized sleep episodes is selectively and dramatically reduced in the advanced stages of the disease. In the present study, melatonin was acutely administered (3 mg/kg SC) to trypanosome-infected rats, before the sleep onset. This treatment resulted in a significant increase of the length of synchronized sleep episodes in respect to the infected animals and to those that had received only the vehicle. Thus, melatonin restored a normal sleep pattern during the infection. Similar findings were obtained with the new melatonin agonist S-20098. The sleep parameters were not significantly modified by either melatonin or S-20098 acute administration to noninfected animals. These findings indicate that exogenous melatonin and S-20098 exert a selective regulatory action on sleep fragmentation during experimental trypanosomiasis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8846114     DOI: 10.1016/0361-9230(95)02032-2

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  11 in total

1.  Clock gene expression during chronic inflammation induced by infection with Trypanosoma brucei brucei in rats.

Authors:  Gabriella B S Lundkvist; Michael T Sellix; Mikael Nygård; Erin Davis; Marty Straume; Krister Kristensson; Gene D Block
Journal:  J Biol Rhythms       Date:  2010-04       Impact factor: 3.182

2.  A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation.

Authors:  Michele Fornaro; Davide Prestia; Salvatore Colicchio; Giulio Perugi
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

3.  Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT1 receptor as well as BDNF expression in the hippocampus during the subjective light phase of rats exposed to chronic constant light.

Authors:  Jana Tchekalarova; Lidia Kortenska; Natasha Ivanova; Milena Atanasova; Pencho Marinov
Journal:  Psychopharmacology (Berl)       Date:  2019-11-13       Impact factor: 4.530

Review 4.  Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.

Authors:  Christian de Bodinat; Béatrice Guardiola-Lemaitre; Elisabeth Mocaër; Pierre Renard; Carmen Muñoz; Mark J Millan
Journal:  Nat Rev Drug Discov       Date:  2010-06-25       Impact factor: 84.694

5.  Agomelatine in the treatment of seasonal affective disorder.

Authors:  Edda Pjrek; Dietmar Winkler; Anastasios Konstantinidis; Matthäus Willeit; Nicole Praschak-Rieder; Siegfried Kasper
Journal:  Psychopharmacology (Berl)       Date:  2006-12-15       Impact factor: 4.530

Review 6.  Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy.

Authors:  Caroline Caddy; Giovanni Giaroli; Thomas P White; Sukhwinder S Shergill; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2014-04

Review 7.  Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.

Authors:  B Guardiola-Lemaitre; C De Bodinat; P Delagrange; M J Millan; C Munoz; E Mocaër
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

8.  The Changes of Expression and Methylation of Genes Involved in Oxidative Stress in Course of Chronic Mild Stress and Antidepressant Therapy with Agomelatine.

Authors:  Paulina Wigner; Ewelina Synowiec; Paweł Jóźwiak; Piotr Czarny; Michał Bijak; Gabriela Barszczewska; Katarzyna Białek; Janusz Szemraj; Piotr Gruca; Mariusz Papp; Tomasz Śliwiński
Journal:  Genes (Basel)       Date:  2020-06-11       Impact factor: 4.096

9.  Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.

Authors:  Amandine Descamps; Colette Rousset; Mark J Millan; Mark Millan; Michael Spedding; Philippe Delagrange; Raymond Cespuglio
Journal:  Psychopharmacology (Berl)       Date:  2009-04-16       Impact factor: 4.530

10.  Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats.

Authors:  Abdeslam Chagraoui; Philippe Protais; Thierry Filloux; Elisabeth Mocaër
Journal:  Psychopharmacology (Berl)       Date:  2003-08-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.